Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
[1] [3] In the pivotal clinical trials (SURPASS program for diabetes and SURMOUNT program for weight management), erectile dysfunction was not identified as a common adverse event, though it's important to note that sexual function was not systematically assessed as a prespecified endpoint in these studies
A closer look at how weight loss drug semaglutide improves the cardiovascular health of obese patients without diabetes Weekly treatments of semaglutide can reduce the risk of cardiovascular death, heart attack or stroke among obese patients without diabetes, according to new data presented at the American Heart Associations Scientific Sessions 2023 conference and simultaneously published in The New England Journal of Medicine .[1] Subcutaneous treatments of semaglutide, a GLP-1 receptor agonist originally developed to treat diabetes, are being sold and marketed by Novo Nordisk under the brand name Wegovy
For instance, in phase 2 trials of SEMA 2.4 g, a substantial reduction in placebo response was observed in composite endpoints of MASH and fibrosis
So, a GLP-1 medication may be helpful as an adjunct in patients who meet criteria for obesity treatment, but patients shouldn't expect it to independently induce remission, I would say
Small human clinical studies in the published literature primarily from Russian researchers (retinitis pigmentosa, pulmonary tuberculosis)
